Literature DB >> 25933681

Relationship between race and clinical characteristics, extent of disease, and response to chemotherapy in patients with low-risk gestational trophoblastic neoplasia.

Izildinha Maestá1, Ross S Berkowitz2, Donald P Goldstein2, Marilyn R Bernstein2, Luz Angela C Ramírez3, Neil S Horowitz2.   

Abstract

OBJECTIVE: To evaluate the potential effects of race on clinical characteristics, extent of disease, and response to chemotherapy in women with postmolar low-risk gestational trophoblastic neoplasia (GTN).
METHODS: This non-concurrent cohort study was undertaken including patients with FIGO-defined postmolar low-risk GTN treated with comparable doses and schedules of chemotherapy at the New England Trophoblastic Disease Center (NETDC) between 1973 and 2012. Racial groups investigated included whites, African American and Asians. Information on patient characteristics and response to chemotherapy (need for second line chemotherapy, reason for changing to an alternative chemotherapy, number of cycles/regimens, need for combination chemotherapy, and time to hCG remission) was obtained.
RESULTS: Of 316 women, 274 (86.7%) were white, 19 (6%) African American, and 23 (7.3%) Asian. African Americans were significantly younger than white and Asian women (p=0.008). Disease presentation, and extent of disease, including antecedent molar histology, median time to persistence, median hCG level at persistence, rate of D&C at persistence, presence of metastatic disease, and FIGO stage and risk score were similar among races. Need for second line chemotherapy (p=0.023), and median number of regimens (p=0.035) were greater in Asian women than in other races.
CONCLUSIONS: Low-risk GTN was more aggressive in Asian women, who were significantly more likely to need second line chemotherapy and a higher number of chemotherapy regimens to achieve complete remission than women of African American and Asian descent. Further studies involving racial differences related to clinical, biological and environmental characteristics are needed.
Copyright © 2015. Published by Elsevier Inc.

Entities:  

Keywords:  Low-risk gestational trophoblastic neoplasia; Racial disparities; Response to chemotherapy

Mesh:

Substances:

Year:  2015        PMID: 25933681     DOI: 10.1016/j.ygyno.2015.04.030

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  4 in total

1.  Impact of clinical characteristics on human chorionic gonadotropin regression after molar pregnancy.

Authors:  Allison A Gockley; Lawrence H Lin; Michelle Davis; Alexander Melamed; Anthony Rizzo; Sue Yazaki Sun; Kevin Elias; Donald P Goldstein; Ross S Berkowitz; Neil S Horowitz
Journal:  Clinics (Sao Paulo)       Date:  2021-08-27       Impact factor: 2.365

2.  Gestational and Non-gestational Trophoblastic Disease. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry No. 032/049, December 2015).

Authors:  C Tempfer; L-C Horn; S Ackermann; M W Beckmann; R Dittrich; J Einenkel; A Günthert; H Haase; J Kratzsch; M C Kreissl; S Polterauer; A D Ebert; K T M Schneider; H G Strauss; F Thiel
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-02       Impact factor: 2.915

3.  A pilot randomized controlled clinical trial of second uterine curettage versus usual care to determine the effect of re-curettage on patients' need for chemotherapy among women with low risk, nonmetastatic gestational trophoblastic neoplasm in Urmia, Iran.

Authors:  Haleh Ayatollahi; Zahra Yekta; Elnaz Afsari
Journal:  Int J Womens Health       Date:  2017-09-21

4.  Dysregulation of Placental Functions and Immune Pathways in Complete Hydatidiform Moles.

Authors:  Jennifer R King; Melissa L Wilson; Szabolcs Hetey; Peter Kiraly; Koji Matsuo; Antonio V Castaneda; Eszter Toth; Tibor Krenacs; Petronella Hupuczi; Paulette Mhawech-Fauceglia; Andrea Balogh; Andras Szilagyi; Janos Matko; Zoltan Papp; Lynda D Roman; Victoria K Cortessis; Nandor Gabor Than
Journal:  Int J Mol Sci       Date:  2019-10-10       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.